KR20210065950A - Ccr3-억제제를 사용한 노화 관련 장애 치료를 위한 방법 및 조성물 - Google Patents

Ccr3-억제제를 사용한 노화 관련 장애 치료를 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20210065950A
KR20210065950A KR1020217008493A KR20217008493A KR20210065950A KR 20210065950 A KR20210065950 A KR 20210065950A KR 1020217008493 A KR1020217008493 A KR 1020217008493A KR 20217008493 A KR20217008493 A KR 20217008493A KR 20210065950 A KR20210065950 A KR 20210065950A
Authority
KR
South Korea
Prior art keywords
alkyl
optionally substituted
group
coo
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217008493A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 피. 브레이스웨이트
에스. 사쿠라 미나미
카롤리 니콜리치
상켓 브이. 레게
아르노 이.제이. 테이처트
Original Assignee
알카헤스트 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알카헤스트 인코포레이티드 filed Critical 알카헤스트 인코포레이티드
Publication of KR20210065950A publication Critical patent/KR20210065950A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217008493A 2018-09-26 2019-09-25 Ccr3-억제제를 사용한 노화 관련 장애 치료를 위한 방법 및 조성물 Withdrawn KR20210065950A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862737017P 2018-09-26 2018-09-26
US62/737,017 2018-09-26
PCT/US2019/052995 WO2020069008A1 (en) 2018-09-26 2019-09-25 Methods and compositions for treating aging-associated impairments using ccr3-inhibitors

Publications (1)

Publication Number Publication Date
KR20210065950A true KR20210065950A (ko) 2021-06-04

Family

ID=69953286

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217008493A Withdrawn KR20210065950A (ko) 2018-09-26 2019-09-25 Ccr3-억제제를 사용한 노화 관련 장애 치료를 위한 방법 및 조성물

Country Status (15)

Country Link
EP (1) EP3856195A4 (https=)
JP (2) JP7528065B2 (https=)
KR (1) KR20210065950A (https=)
CN (1) CN112789044A (https=)
AU (1) AU2019346456A1 (https=)
BR (1) BR112021004938A2 (https=)
CL (1) CL2021000724A1 (https=)
CO (1) CO2021003713A2 (https=)
EA (1) EA202190463A1 (https=)
IL (1) IL281578A (https=)
MA (1) MA53743A (https=)
MX (1) MX2021002967A (https=)
SG (1) SG11202102105VA (https=)
TW (1) TW202027752A (https=)
WO (1) WO2020069008A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113689A1 (en) 2018-09-25 2020-04-02 Antabio Sas Indane derivatives for use in the treatment of bacterial infection

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200538098A (en) * 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
EP1996551A2 (en) * 2006-03-07 2008-12-03 AstraZeneca AB Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them.
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
MX2011011080A (es) 2009-04-22 2012-02-23 Axikin Pharmaceuticals Inc Antagonistas de ccr3 de arilsulfonamida 2, 5-disustituida.
US20160208011A1 (en) * 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
MY199462A (en) * 2017-04-05 2023-10-30 Alkahest Inc Methods and compositions for treating retina-associated disease using ccr3-inhibitors
CN110636844A (zh) * 2017-04-05 2019-12-31 万能溶剂有限公司 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物

Also Published As

Publication number Publication date
BR112021004938A2 (pt) 2021-06-01
JP7528065B2 (ja) 2024-08-05
MA53743A (fr) 2022-01-05
TW202027752A (zh) 2020-08-01
CO2021003713A2 (es) 2021-04-08
AU2019346456A1 (en) 2021-04-15
JP2024153742A (ja) 2024-10-29
EP3856195A4 (en) 2022-06-22
CN112789044A (zh) 2021-05-11
EA202190463A1 (ru) 2021-06-29
CL2021000724A1 (es) 2021-10-15
SG11202102105VA (en) 2021-04-29
MX2021002967A (es) 2021-08-11
IL281578A (en) 2021-05-31
JP2022502441A (ja) 2022-01-11
CA3111433A1 (en) 2020-04-02
EP3856195A1 (en) 2021-08-04
WO2020069008A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
TWI791507B (zh) 使用ccr3-抑制劑治療老化相關損傷之方法及組合物
JP6861764B2 (ja) 軸索再生および神経機能を促進するための方法および組成物
US10555916B2 (en) NMDAR antagonist for the treatment of pervasive development disorders
US20200054622A1 (en) Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors
UA119538C2 (uk) Лікування злоякісної пухлини дигідропіразинопіразинами
JP2024153742A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物
US20100247688A1 (en) Pirenzepine and derivatives thereof as anti-amyloid agents
CN113924087A (zh) 血清素4受体激动剂对抗应激的预防功效
CA3111433C (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
JP2019516696A (ja) 純粋な５−ｈｔ６受容体アンタゴニストのｎｍｄａ受容体アンタゴニストとの組合せ
ES3062815T3 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
HK40053020A (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
US11213494B2 (en) Compositions and methods for the treatment of pervasive development disorders
EA041892B1 (ru) Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов
HK40019123A (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
WO2025188952A1 (en) Fused amino pyrimidine compounds for treatment of synucleinopathies and tdp-43 proteinopathies
JP2017532324A (ja) 疼痛の治療のためのｂｌｔ２アゴニスト
TW202539621A (zh) 用於治療巴金森氏症的治療劑
HK1217896B (en) Compositions and methods for the treatment of pervasive development disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210322

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid